Hybio Pharmaceutical Tangible Net Worth Ratio
Hybio Pharmaceutical tangible net worth ratio. Hybio Pharmaceutical (300199) has a Tangible Net Worth Ratio of 36.6% as of September 2025. This metric is calculated by deducting intangible assets (CN¥422.37 Million) from net assets (CN¥666.08 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore how fast is Hybio Pharmaceutical growing its equity to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Tangible Net Worth Ratio of Hybio Pharmaceutical (2007–2024)
Tangible net worth ratio of Hybio Pharmaceutical from 2007 to 2024. This chart shows how Hybio Pharmaceutical's Tangible Net Worth Ratio has changed across 18 annual periods from 2007 to 2024. As of September 2025, the ratio stands at 36.6%, reflecting net assets of CN¥666.08 Million with intangible assets of CN¥422.37 Million CNY. Check 300199 capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Hybio Pharmaceutical Tangible Net Worth Ratio by Year (2007–2024)
Hybio Pharmaceutical tangible net worth ratio by year from 2007 to 2024. The table below presents the year-by-year Tangible Net Worth Ratio for Hybio Pharmaceutical from 2007 to 2024, covering 18 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For live market cap and overall valuation, see Hybio Pharmaceutical stock valuation.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 28.0% | CN¥597.05 Million | CN¥430.09 Million | CN¥3.01 Billion | ▼ -17.2 pp |
| 2023 | 45.2% | CN¥783.21 Million | CN¥429.59 Million | CN¥3.28 Billion | ▼ -15.7 pp |
| 2022 | 60.9% | CN¥1.30 Billion | CN¥507.30 Million | CN¥3.61 Billion | ▼ -10.0 pp |
| 2021 | 70.9% | CN¥1.65 Billion | CN¥479.20 Million | CN¥3.91 Billion | ▲ +3.8 pp |
| 2020 | 67.2% | CN¥1.68 Billion | CN¥550.89 Million | CN¥4.02 Billion | ▼ -8.1 pp |
| 2019 | 75.2% | CN¥2.23 Billion | CN¥552.89 Million | CN¥4.72 Billion | ▼ -9.4 pp |
| 2018 | 84.6% | CN¥3.39 Billion | CN¥521.03 Million | CN¥5.66 Billion | ▼ -3.7 pp |
| 2017 | 88.3% | CN¥3.88 Billion | CN¥453.90 Million | CN¥5.30 Billion | ▲ +1.4 pp |
| 2016 | 86.9% | CN¥3.60 Billion | CN¥471.82 Million | CN¥4.46 Billion | ▲ +4.6 pp |
| 2015 | 82.3% | CN¥2.64 Billion | CN¥467.05 Million | CN¥3.55 Billion | ▼ -12.9 pp |
| 2014 | 95.2% | CN¥1.30 Billion | CN¥62.70 Million | CN¥1.70 Billion | ▲ +0.2 pp |
| 2013 | 95.0% | CN¥1.12 Billion | CN¥56.28 Million | CN¥1.29 Billion | ▼ -3.6 pp |
| 2012 | 98.6% | CN¥1.02 Billion | CN¥14.23 Million | CN¥1.12 Billion | ▲ +0.2 pp |
| 2011 | 98.4% | CN¥976.09 Million | CN¥15.48 Million | CN¥1.04 Billion | ▲ +5.4 pp |
| 2010 | 93.0% | CN¥180.59 Million | CN¥12.58 Million | CN¥212.89 Million | ▲ +3.1 pp |
| 2009 | 89.9% | CN¥127.74 Million | CN¥12.84 Million | CN¥182.47 Million | ▲ +2.8 pp |
| 2008 | 87.2% | CN¥99.23 Million | CN¥12.72 Million | CN¥136.55 Million | ▼ -12.8 pp |
| 2007 | 100.0% | CN¥48.70 Million | CN¥0.00 | CN¥58.24 Million | — |